Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Trends in PSA Utilization in Primary Care Physicians

May 19, 2015
By Ryan Werntz, MD
Publication
Article
Special ReportsGenitourinary (Issue 2)
Issue 2

Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.

Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.

<<<

View more from the GU Cancers Special Report

Articles in this issue

Use of ARN-509 in Prostate Cancer
Use of ARN-509 in Prostate Cancer
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPC
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPC
Multiparametric MRI Effective, Affordable for Prostate Cancer Detection
Multiparametric MRI Effective, Affordable for Prostate Cancer Detection
Study Illuminates Role of AR-V7 in Carcinogenesis
Study Illuminates Role of AR-V7 in Carcinogenesis
Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC
PSA Screening Drops 50% Following USPSTF Recommendation
PSA Screening Drops 50% Following USPSTF Recommendation
Urine-Based Diagnostic Effectively Identifies Prostate Cancer
Urine-Based Diagnostic Effectively Identifies Prostate Cancer
Trends in PSA Utilization in Primary Care Physicians
Trends in PSA Utilization in Primary Care Physicians
AR-V7 as a Biomarker in CRPC
AR-V7 as a Biomarker in CRPC

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Tony Berberabe, MPH
May 16th 2025
Article

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.

Read More


Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen


Dostarlimab Shows Response in Endometrial Cancer

Dostarlimab Shows Response in Endometrial Cancer

Ashling Wahner
May 14th 2025
Article

Read More


Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen


Atezolizumab/Ipatasertib Demonstrates Potential in Solid Tumors

Atezolizumab/Ipatasertib Demonstrates Potential in Solid Tumors

Morgan Bayer
May 14th 2025
Article

Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies Congress 2025.

Read More


Frontline Dato-DXd Looks Promising in NSCLC

Frontline Dato-DXd Looks Promising in NSCLC

Morgan Bayer
May 13th 2025
Article

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Read More

Related Content

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Tony Berberabe, MPH
May 16th 2025
Article

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.

Read More


Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen


Dostarlimab Shows Response in Endometrial Cancer

Dostarlimab Shows Response in Endometrial Cancer

Ashling Wahner
May 14th 2025
Article

Read More


Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen


Atezolizumab/Ipatasertib Demonstrates Potential in Solid Tumors

Atezolizumab/Ipatasertib Demonstrates Potential in Solid Tumors

Morgan Bayer
May 14th 2025
Article

Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies Congress 2025.

Read More


Frontline Dato-DXd Looks Promising in NSCLC

Frontline Dato-DXd Looks Promising in NSCLC

Morgan Bayer
May 13th 2025
Article

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.